https://www.selleckchem.com/pr....oducts/Tebipenem-piv
6±2.0mmol/l) with 67.1% in the target range during Ramadan. The incidence of hypoglycemia in the whole group (2.9 v 2.9) and in the SU+ (3.7 vs 3. and BI+ (1.7 vs 2.9) groups and eHbA1c (P=0.56, P=0.93), average glucose (P=0.56, P=0.92) and time within range (P=0.63, P=0.73) did not change in the SU+ and BI+ groups, respectively, before and during Ramadan. Structured education with adjustment of the dose of glucose lowering medication alongside use of the FGMS can effectively mitigate the increased risk of hypoglycemi
إعجاب
علق
شارك
